US stock · Healthcare sector · Biotechnology
C
Cassava Sciences, Inc.
SAVA
NASDAQ22.87
USD
-0.36
(-1.55%)
Market Closed
-12.65P/E
-13Forward P/E
-0.52P/E to S&P500
954.809MMarket CAP
- -Div Yield
Upcoming Earnings
1 Aug-7 Aug
Shares Short
5/15/23
10.16M
Short % of Float
25.84%
Short % of Shares Outs.
24.34%
% Held by Insiders
6.01%
% Held by Institutions
27.18%
Beta
-0.14
PEG Ratio
-0.34
52w. high/low
51.59/13.84
Avg. Daily Volume
0.72M
Return %
Stock
S&P 500
1 year
(19.63)
3.92
3 years
756.46
34.34
5 years
133.74
55.95
Scale: |
High
Low
75.11
38.50
46.97
22.40
61.81
29.68
73.15
22.96
41.02
16.38
38.99
15.05
43.54
11.27
25.55
10.71
21.00
3.57
9.31
3.10
12.80
0.76
7.20
0.84
12.68
1.63
146.16
6.78
62.49
13.84
38.53
21.45
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
10.46
10.56
3.41
2.76
1.82
1.70
6.40
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.00)
Earnings per share
3.22
2.54
(0.58)
(1.97)
(0.41)
(0.54)
4.91
(1.92)
(2.16)
(2.28)
(1.82)
(0.61)
(0.27)
(0.24)
(0.82)
(1.90)
(1.89)
FCF per share
0.24
1.50
(2.44)
(0.02)
(0.04)
(1.12)
(1.08)
(1.49)
(1.41)
(1.89)
(1.26)
(0.45)
(0.15)
(0.22)
(1.33)
(2.00)
(1.72)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.11
0.35
- -
- -
- -
- -
- -
0.01
0.03
0.01
- -
- -
0.00
0.01
0.56
0.07
0.07
Book Value per sh.
16.48
17.28
17.97
5.41
7.04
2.05
7.51
6.19
4.49
2.86
1.48
1.84
1.27
3.53
6.44
5.66
5.22
Comm.Shares outs.
6
6
6
6
6
6
6
6
7
7
7
11
17
26
39
40
41
Avg. annual P/E ratio
19.6
23.1
(60.9)
(22.1)
(102.9)
(52.3)
4.6
(15.4)
(6.3)
(5.5)
(2.4)
(7.4)
(5.5)
(26.7)
(72.0)
(18.0)
(12.6)
P/E to S&P500
1.1
1.1
(0.9)
(1.1)
(6.3)
(3.5)
0.3
(0.8)
(0.3)
(0.2)
(0.1)
(0.3)
(0.2)
(0.7)
(2.4)
(0.9)
(0.5)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
66
64
21
17
11
11
41
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0
Operating margin
15.4%
13.7%
(32.8)%
(81.5)%
(30.6)%
(35.8)%
76.3%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
- -
(Infinity)%
Depreciation (m)
0
0
0
0
0
0
- -
0
0
0
0
0
0
0
1
1
- -
Net profit (m)
20
15
(3)
(12)
(3)
(3)
32
(12)
(14)
(15)
(12)
(7)
(5)
(6)
(32)
(76)
(77)
Income tax rate
- -
(4.2)%
30.3%
- -
- -
- -
(0.2)%
- -
- -
- -
- -
- -
- -
- -
- -
- -
7.6%
Net profit margin
30.8%
24.1%
(16.9)%
(71.5)%
(22.8)%
(31.6)%
76.7%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
Working capital (m)
185
171
160
84
85
47
48
40
29
18
10
20
22
92
232
204
181
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0
0
0
- -
Equity (m)
104
104
108
33
44
13
48
40
29
19
10
20
22
92
254
228
204
ROIC
10.9%
8.9%
(2.1)%
(14.1)%
(3.0)%
(7.4)%
65.3%
(30.9)%
(48.2)%
(79.7)%
(122.8)%
(33.4)%
(21.0)%
(6.9)%
(12.7)%
(33.5)%
(40.2)%
Return on capital
9.8%
7.6%
(2.7)%
(12.1)%
(2.6)%
(6.1)%
62.8%
(30.3)%
(44.3)%
(76.9)%
(110.0)%
(32.6)%
(19.7)%
(6.7)%
(12.1)%
(32.5)%
(40.7)%
Return on equity
19.5%
14.7%
(3.2)%
(36.5)%
(5.9)%
(26.2)%
65.3%
(30.9)%
(48.2)%
(79.7)%
(122.8)%
(33.4)%
(21.0)%
(6.9)%
(12.8)%
(33.5)%
(37.5)%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
74.3%
277.7%
- -
- -
- -
- -
7.5%
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
1 May · 2023 | Q1
All numbers in millions
Total liabilities
$ 14
Total assets
$ 218
Long-term debt
$ - -
Cash and equiv.
$ 187
Goodwill
$ - -
Retained earnings
$ (308)
Common stock
42
Enterprise Value
$ 767
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
94
233
201
Receivables
- -
- -
- -
Inventory
- -
- -
- -
Other
0
151
118
Current assets
94
244
211
Acc. Payable
1
7
4
Debt due
0
0
0
Other
1
5
3
Current liabilities
2
13
7
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
- -
- -
- -
Cash flow
53.07%
236.84%
104.44%
Earnings
135.44%
138.53%
41.03%
Dividends
- -
- -
- -
Book value
(10.39)%
123.70%
52.10%
Insider Trading
Type
Shares
Date
Barbier Remi
Exempt
14,285
05/24/23
Barbier Remi
InKind
9,545
05/24/23
Barbier Remi
Exempt
71,428
05/24/23
Barbier Remi
InKind
47,723
05/24/23
Barbier Remi
Exempt
71,428
05/24/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
(0)
(0)
2023
- -
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
(0.09)
(0.13)
(0.24)
(0.35)
(0.81)
2022
(0.43)
(0.46)
(0.48)
(0.43)
(1.79)
2023
(0.52)
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Remi Barbier
Full-time employees:
26
City:
Austin
Address:
7801 North Capital of Texas Highway
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Recent News
· 22 Dec, 2021 · The Wall Street Journal
· 17 Nov, 2021 · The Wall Street Journal